Trial Profile
A Trial Comparing Efficacy and Safety of NN1250 and Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™: LOW VOLUME)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms BEGIN; BEGIN-LOW-VOLUME
- Sponsors Novo Nordisk
- 28 May 2013 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
- 09 Dec 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 09 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.